APpendix derived PAncreatic cancer Reactive T-lymphocytes

Completed

• Conditions: pancreatic cancer; pancreatic ductal adenocarcinoma; 10015674; 10017991

• Registration Number: NL-OMON55377
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 50

Inclusion Criteria

• Age between 35 and 80 years.
• Histological or cytological confirmed pancreatic cancer (i.e. pancreatic
ductal adenocarcinoma).
• Planned diagnostic laparoscopy for LAPC or planned resection for
(borderline) resectable PDAC.
• Ability to undergo diagnostic laparoscopy and appendectomy.
• Written informed consent.

Exclusion Criteria

• Previous appendectomy.
• Previous malignancy (excluding non-melanoma skin cancer), unless no evidence
of disease and diagnosed more than 5 years before diagnosis of pancreatic
cancer.
• Pregnancy.
• Serious concomitant systemic disorders that would compromise the safety of
the patient or his/her ability to complete the study, at the discretion of the
investigator.
• Use of immune suppressive medication in the past 3 months ( including TNF-a
antibody, azathioprine, mercaptopurine, methotrexaat, ciclosporin, adalimumab,
infliximab, or vedolizumab therapy).

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>To identify tumour specific oncolytic activity of VA-GALT derived T cells in<br /><br>patients with pancreatic cancer.</p><br>